Objective
The ongoing pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections has led to more than 7.031.249 cases and 403.112 deaths globally as of June 8, 2020. Although most infections are self-limited, about 15% of infected adults develop severe pneumonia that requires treatment with supplemental oxygen and an additional 5% progress to critical illness with hypoxaemic respiratory failure, acute respiratory distress syndrome, and multiorgan failure that necessitates ventilatory support, often for several weeks.
Worldwide, infections and death from SAR-CoV-2 continue during June with more than 110.000 new cases every day despite lockdown in Europe and oversees. What started as a temporary sanitary issue, has morphed into a more permanent and long-lasting pan epidemic outbreak. One efficient manner to limit COVID-19 spreading and an adequate mean of better managing the COVID-19 outbreak is through unrestrained availability of fast, efficient, accurate and cost-effective point-of-care tests (POCT). Here we propose C-POCT-S, a rapid (<30 min), sensitive (200 vps/mL), selective (SARS-CoV-2), and inexpensive ( < 20 Euros) solution to address this medical need. C-POCT-S is based on a combination of several technologies such as the use of COVID-19 specific nanobodies (VHH), magnetic nanoparticles with high magnetic strength and a VHH modified interfaces, all integrated in a a hand-held surface plasmon resonance (SPR) based POC test (C-POCT-S) for the screening of the presence/absence of the SARS-CoV-2 virus in nasal and salvia samples.
The aim of this project is to complete product optimization, performance validation in a clinical setting and manufacturing quality control for C-POCT-S and completion of its technical file, to enable declaration of conformity and affixing of CE mark.
Fields of science
- medical and health sciencesclinical medicinepneumology
- natural sciencesbiological sciencesmicrobiologyvirology
- medical and health scienceshealth sciencespublic healthepidemiologypandemics
- medical and health scienceshealth sciencesinfectious diseasesRNA virusescoronaviruses
- engineering and technologynanotechnologynano-materials
Programme(s)
Call for proposal
H2020-SC1-PHE-CORONAVIRUS-2020-2
See other projects for this callSub call
H2020-SC1-PHE-CORONAVIRUS-2020-2-CNECT
Funding Scheme
IA - Innovation actionCoordinator
59000 Lille
France
See on map
Participants (7)
13284 Marseille
See on map
Legal entity other than a subcontractor which is affiliated or legally linked to a participant. The entity carries out work under the conditions laid down in the Grant Agreement, supplies goods or provides services for the action, but did not sign the Grant Agreement. A third party abides by the rules applicable to its related participant under the Grant Agreement with regard to eligibility of costs and control of expenditure.
75794 Paris
See on map
1348 Louvain La Neuve
See on map
A94A306 Monkstown Dublin
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
9976100 Neveh Shalom
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
59037 Lille
See on map
95650 Boissy-l'aillerie
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.